Anti-Infectives: World Markets, 2nd Edition, Vol. I-III (Complete Series)
Loading...
Published May 1, 2007 |
540 Pages |
Pub ID: KLI1477668
This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic competition.
- Antifungals
- Antibacterials
- Antivirals
- Epidemiology including Incidence Statistics for each type of infection.
- Current Market Size and Revenue Forecasts for each market segment to assist with long term planning.
- Discussion of Competitive Products in the market and new products in the delivery pipeline.
- Coverage of Generic Threats for affected major products.
- Round-Up of the Key Players in each area of anti-infectives.
- Over 195 Tables and Figures for easy access to information and decision support tools, internal emails, memos and presentations.
- Discussion of Unique Issues and Emerging Trends for each antibiotic area.
- Market Share of Leading Competitors for each area.
- U.S., Europe, Japan and Rest of World market data.
Vol. I: Antifungals
Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis
CHAPTER ONE: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: Introduction
- Overview
- Introduction to Pathogens
- Antimicrobial Spectrum
- Bacterial Resistance
- Principles of Anti-infective Therapy
- Infecting Organism
- Antibiotic Sensitivity Testing
- Site of Infection
- Host Defenses and Organ Function
- Antibiotic Pharmcokinetics
- Monitoring Therapy
- Combination Therapy and Prophylactic Use
- Fungal Infections
- Types of Fungal Infections
- Superficial
- Systemic
- Histoplasmosis
- Coccidioidomycosis
- Blastomycosis
- Demographics and Statistics
CHAPTER THREE: Systemic Antifungal Drugs
- Overview
- Description of Products
- Allylamines
- Terbinafine (Lamisil - Novartis)
- Azoles
- Fluconazole (Diflucan - Pfizer)
- Ketoconazole (Nizoral, Johnson & Johnson)
- Miconazole (Monistat, Johnson & Johnson)
- Itraconazole (Sporanox, Johnson & Johnson)
- Posaconazole (Noxafil, Schering-Plough)
- Virconazole (Vfend, Pfizer)
- Polyene Macrolides
- Amphotericin B (Ambisome, Astellas; Abelcet, Enzon; Fungizone, Apothecon).
- Griseofluvin (Fulvicin, Schering)
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Flucytosine (Ancoban, Valeant)
- Echinocandins
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FOUR: Topical Antifungal Drugs
- Overview
- Description of Products
- Allylamines
- Naftifine (Naftin, Allergan)
- Terbinafine (Lamisil - Novartis)
- Butenafine (Mentax, Bertek)
- Azoles
- Miconazole (Monistat -Derm, OrthoDermatological)
- Clotrimazole (Mycelex, Bayer; Lotrimin, Schering)
- Ketoconazole (Nizoral, J&J; Xolegel, Barrier Therapeutics)
- Oxiconazole (Oxistat, GlaxoSmithKline/Elan)
- Econazole (Spectazole, Ortho Dermatological)
- Sulconazole (Exelderm, Westwood-Squibb)
- Terconazole (Terazol, Ortho Dermatological)
- Polyene Macrolides
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Ciclopirox (Penlac, Sanofi-Aventis/Dermik)
- Selenium sulfide (Selsun, Chattem Inc)
- Amorolfine (Loceryl, Roche)
- Alcortin (Iodoquinol, hydrocortisone, Primus Pharmaceuticals)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FIVE: Issues and Trends Affecting the Antifungal Market
- Introduction
- Fungal Infections and Immunocompromised Patients
- Reimbursement
- Infection Imaging
- Expanded Use of Azoles
- Drug Resistance and Interactions
- Standardized Susceptibility Testing
- Generic Impact and Availability
- Importance of Drug Delivery
- Rx-to-OTC Switches
- The Antifungal Market and Enchiocandins
chapter six: Antifungal Drugs: Total Market Size and Forecast
- Overview
- Total market Size and Forecast
CHAPTER SEVEN: Corporate Profiles
- Introduction
- Astellas Pharma Inc
- Barrier Therapeutics, Inc
- Johnson & Johnson Group
- Merck & Company, Inc
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc
- Schering-Plough Corporation
CHAPTER EIGHT: Company Directory
table of exhibits
Chapter One: Executive Summary
- Table 1-1: The World Market for Antifungal Drugs 2004-2011
- Figure 1-1: The World Market for Antifungal Drugs 2004-2011
Chapter Two: Introduction
- Table 2-1: Estimated World and U.S. Incidence of Fungal Infections (thousands)
- Figure 2-1: Estimated World and U.S. Incidence of Leading Fungal Infections
- Table 2-2: World Population by Selected Geographical Region, 2006-2050
- Figure 2-2: World Population by Selected Geographical Region, 2006-2050
- Table 2-3: Estimated World Population by Age and Geographical Region, 2006
- Figure 2-3: Estimated World Population by Age and Geographical Region, 2006
- Table 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
- Figure 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
Chapter Three: Systemic Antifungal Drugs
- Table 3-1: Allylamines
- Table 3-2: Azoles
- Table 3-3: Polyene Macrolides
- Table 3-4: Miscellaneous Antifungals
- Table 3-5: New Generic Drug Approvals for Systemic Antifungals, United States, 2004-2006
- Table 3-6: Systemic Antifungal Drugs in Development
- Table 3-7: The Market for Systemic Antifungal Drugs 2004-2011
- Figure 3-1: Systemic Antifungal Drug Market 2004-2011
- Table 3-8: Systemic Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2004-2010
- Figure 3-2 : Systemic Antifungal Drug Market Revenues and Distribution by Product Type, 2004-2010
- Figure 3-3: Systemic Antifungal Drug Market Share of Revenues by Product Type 2004-2011
- Figure 3-4: Systemic Antifungal Drug Market Share by Product Type 2006 and 2011
- Table 3-9: Systemic Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
- Figure 3-5: Systemic Antifungal Drug Market Market Share by Infection Type, 2006
- Table 3-10: Systemic Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
- Figure 3-6: Systemic Antifungal Drug Market Market Share by Geographic Region, 2006
- Table 3-11: Systemic Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
- Figure 3-7: Systemic Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
- Table 3-12: Systemic Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
- Figure 3-8: Systemic Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
- Table 3-13: Systemic Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
- Figure 3-9: Systemic Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006
Chapter Four: Topical Antifungal Drugs
- Table 4-1: Allyamines
- Table 4-2: Topical Azoles
- Table 4-3: Polyene Macrolides
- Table 4-4: Miscellaneous Antifungals
- Table 4-5: New Generic Drug Approvals for Topical Antifungals,
- United States, 2004-2006
- Table 4-6: Topical Antifungal Drugs in Development
- Table 4-7: Topical Antifungal Drug Market, 2004-2011
- Figure 4-8: Topical Antifungal Drug Market, 2004-2011
- Table 4-8: Topical Antifungal Drug Market, 2004-2011
- Figure 4-9: Topical Antifungal Drug Market by Product Type - Revenues, 2004-2011
- Figure 4-10: Topical Antifungal Drug Market by Product Type -Percent Distribution, 2004-2011
- Figure 4-4: Topical Antifungal Drug Market Share by Product Type 2006 and 2011
- Table 4-9: Topical Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
- Figure 4-5: Topical Antifungal Drug Market Market Share by Infection Type, 2006
- Table 4-10 : Topical Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
- Figure 4-6: Topical Antifungal Drug Market Market Share by Geographic Region, 2006
- Table 4-11: Topical Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
- Figure 4-7: Topical Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
- Table 4-12: Topical Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
- Figure 4-8: Topical Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
- Table 4-13: Topical Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
- Figure 4-9: Topical Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006
Chapter Five: Issues and Trends Affecting the
- Antifungal Market
- Table-5-1: New Generic Drug Approvals for Antifungals, United States, 2004-2006
- Table 5-2: Selected Antifungal Rx-to-OTC Switches
Chapter Six: Antifungal Drugs: Total Market
- Size and Forecast
- Table 6-1: The World Market for Antifungal Drugs 2004-2011
- Figure 6-1: The World Market for Antifungal Drugs 2004-2011
- Table 6-2: Topical Antifungal Drug Market by Type (Topical vs Systemic) 2004-2011
- Figure 6-2: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2004-2011
- Figure 6-3: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2006 and 2011
Vol II: Antibacterials
Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Introduction The World Market for Anti-Infectives Volume 2:
- Antibacterial Drugs
- Introduction to pathogens
- Classification of Antibacterial Organisms
- Antimicrobial Spectrum
- Bacterial Resistance
- Principles of Anti-infective Therapy
- Infecting Organism
- Antibiotic Sensitivity Testing
- Site of Infection
- Host Defenses and Organ Function
- Antibiotic Pharmacokinetics
- Monitoring Therapy
- Combination Therapy and Prophylactic Use
- Demographics and Statistics
Issues and Trends Affecting the Antibacterial Drug Market
- introduction
- Drug Resistance and Interactions
- Antibiotic Abuse
- Antibiotic Cycling
- addressing market trends
- Antibiotic use in Agriculture
- Antibiotic Education
- Children and Bacterial resistance
- The Elderly and Bacterial Resistance
- Compromised Individuals and Bacterial Resistance
- Screening Hospitalized patients
- Side Effects of Antibiotics
- Partnerships and Alliances
- Environment and Drug Resistance
- Methicillin-resistant Staphylococcus Aureus (MRSA)
Cephalosporin Antibiotics
- Overview
- Description of Products
- First Generation Cephalosporins
- Cephalexin (Keflex, Advancis Pharmaceuticals)
- Cefazolin (Ancef, GlaxoSmithKline; Cefamezin, Astellas)
- Cefadroxil (Duricef, Bristol-Myers Squibb/Warner Chilcot)
- Second Generation Cephalosporins
- Cefuroxime (Ceftin, GlaxoSmithKline)
- Cefoxitin (Mefoxin, Merck)
- Third Generation Cephalosporins
- Cefotaximen (Claforan offered by Sanofi-Aventis)
- Cefoperazone (Cefobid, Pfizer)
- Ceftibutin (Cedax, Shionogi)
- Ceftizoxime (Cefizox, Astellas)
- Ceftriaxone (Rocephin, Roche)
- Ceftazidime (Fortaz, GlaxoSmithKline)
- Cefixime (Suprax, Wyeth/Lupin Pharmaceuticals)
- Cefpodoxime (Vantin, Pfizer)
- Fourth Generation Cephalosporins
- Cefepime (Maxipime, Bristol-Myers Squibb)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Macrolide Antibiotics
- Overview
- Description of Products
- Azithromycin (Zithromax, Pfizer; Zmax, Pfizer)
- Clarithromycin (Biaxin, Abbott Laboratories)
- Erythromycin (Erythrocin, Abbott Laboratories; EryPed, Abbott Laboratories)
- Telithromycin (Ketek, Sanofi-Aventis)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Penicillin Antibiotics
- Overview
- Natural Penicillins
- Penicillinase-Resistant Penicillins
- Broad -Spectrum Penicillins
- Extended-Spectrum Penicillins
Description of Products
- Natural Penicillins
- Penicillin G (Bicillin, King Pharmaceuticals; Pfizerpen, Pfizer)
- Penicillinase-resistant Penicillins
- Cloxacillin (Cloxapen, GlaxoSmithKline)
- Oxacillin (Bactocill, GlaxoSmithKline)
- Broad-spectrum Penicillins
- Amoxicillin (Augmentin, GlaxoSmithKline; Amoxil,GlaxoSmithKline)
- Ampicillin (Unasyn, Pfizer)
- Extended-spectrum Penicillins
- Carbenicillin (Geocillin, Pfizer)
- Piperacillin (Pipracil, Wyeth; Zosyn, Wyeth)
- Ticarcillin (Timentin, GlaxoSmithKline)
Quinolone Antibiotics
- Overview
- Description of Products
- Ciprofloxacin (Cipro, Bayer; Proquin XR, Depomed)
- Gemifloxacin (Factive, LG Chem Ltd. and Oscient Pharmaceuticals)
- Lomefloxacin (Maxaquin, Unimed)
- Nalidixic (NegGram, Sanofi-Aventis)
- Norfloxacin (Noroxin, Merck)
- Ofloxacin (Floxin, Ortho-McNeil)
- Moxifloxicin (Avelox, Bayer; Vigamox, Alcon)
- Levofloxacin (Levaquin, Ortho-McNeil; Tavanic, Sanofi-Aventis; Cravit, Daiichi Sankyo; Quixin, Santen)
- Gatifloxacin (Zymar, Allergan/Kyorin)
- Trovafloxacin (Trovan, Pfizer)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Sulfonamide Antibiotics
- Overview
- Description of Products
- Sulfisoxazole (Gantrisin Pediatric, Roche)
- Oxytetracycline/Sulfamethizole/Phenazopyridine (Urobiotic, Pfizer)
- Erythromycin ethylsuccinate and Sulfisoxazole acetyl (Pediazole, Ross)
- Dapsone (Aczone Gel, QLT USA-Tolmar Inc.)
- Research and Development
- Market Size and Growth
- Competitive Analysis
Tetracycline Antibiotics
- Overview
- Description of Products
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Other Miscellaneous Antibiotics
- Overview
- Description of Products
- Aminoglycosides
- Amikacin Sulfate (Amikin, Bristol-Myers Squibb)
- Kanamycin Sulfate (Kantrex, Bristol-Myers Squibb)
- Neomycin Sulfate (Neo-fradin, X Gen Pharms)
- Streptomycin Sulfate (Streptomycin, Pfizer)
- Lincomycin
- Clindamycin (Cleocin, Pfizer; Clindesse, KV Pharmaceutical Company; Evoclin, Connetics Corp.; Ziana Gel, Medicis/Dow)
- Chloramphenicol
- Chloramphenicol (Chloromycetin,Pfizer)
- Glycopeptide
- Vancomycin (Vancocin, Viropharma)
- Monobactams
- Aztreonam (Azactam, Bristol-Myers Squibb)
- Carbapenems
- Imipenem/cilastatin (Primaxin, Merck)
- Meropenem (Merrem, AstraZeneca)
- Metronidazole
- Metronidazole (Flagyl, Pfizer; Pylera, Axcan; Metrogel-Vaginal, 3M Pharmaceuticals; MetroGel, Galderma)
- Antituberculars
- Rifampicin (Rifater, Sanofi-Aventis)
- Capreomycin (Capastat sulfate, Eli Lilly & Co.)
- Ethionamide (Trecator SC, Wyeth)
- Aminosalicylic acid granules (Paser Granules, Jacobus Pharmaceutical)
- Cycloserine (Seromycin, Eli Lilly & Co.)
- Antileprotics
- Dapsone (Dapsone, Jacobus)
- Oxazolidinones
- Linezolid (Zyvox, Pfizer)
- Ketolides
- Telithromycin (Ketek, Sanofi-Aventis)
- Lipopeptides
- Daptomycin (Cubicin, Cubist Pharmaceutical)
- Glycyclines
- Tigecycline (Tygacil, Wyeth)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Corporate Profiles
- Introduction
- Abbott Laboratories
- AstraZeneca plc
- Bayer Schering Pharma AG
- Cubist Pharmaceuticals, Inc
- Daiichi Sankyo Co., Ltd.
- GlaxoSmithKline
- Johnson & Johnson Group
- King Pharmaceuticals, Inc.
- Merck & Company, Inc.
- Pfizer, Inc.
- Roche
- Sanofi-Aventis
- Wyeth
Company Names and Addresses
Volume III: Antivirals
Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction
- Introduction to Viruses
- Examples of Pathogenic Viruses
- Virus Function and Life History
- Replication in DNA Viruses
- Replication of RNA Viruses
- Replication in Retroviruses
- Host Defenses Against Viruses
- Viral Ploys to Invade Host Cells and Circumvent Host Responses
- Invasion of Host Cells
- Subversion of the Immune Response
- Avoidance of Immune Detection and Attack by Killer Cells
- HIV and AIDS
- Demographics and Epidemiology
- Cytomegalovirus
- Hepatitis B Virus
- Hepatitis C Virus (HCV)
- Herpes
- Human Immunodeficiency Virus (HIV)
- Human Papillomavirus (HPV)
- Influenza
- Respiratory Syncytial Virus (RSV)
- Population Demographics
Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors
- Overview
- Description of Products
- Nucleoside Reverse Transcriptase Inhibitors
- Zidovudine (Retrovir, GlaxoSmithKline)
- Didanosine (Videx, Bristol-Myers Squibb)
- Zalcitabine (Hivid, Roche)
- Lamividine(Epivir, GlaxoSmithKline; Zeffix, GlaxoSmithKline)
- Stavudine (Zerit, Bristol-Myers Squibb)
- Abacavir (Ziagen, GlaxoSmithKline)
- Nucleotide Analogue Reverse Transcriptase Inhibitors
- Tenofovir (Viread, Gilead Sciences)
- Adefovir dipivoxil (Hepsera, Gilead Sciences)
- Combination Nucleoside Reverse Transcriptase Inhibitors
- Lamivudine and Zidovudine (Combivir, GlaxoSmithKline)
- Abacavir and Lamivudine (Kivexa, GlaxoSmithKline)
- Abacavir sulfate, Lamivudine and Zidovudine (Trizivir, GlaxoSmithKline)
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Nevirapine (Viramune, Boehringer Ingelheim)
- Efavirenz (Sustiva, Bristol-Myers Squibb Oncology)
- Delavirdine mesylate (Rescriptor, Agouron Pharmaceuticals)
- Emtricitabine (Emtriva, Gilead Sciences)
- DNA Polymerase Inhibitors
- Acyclovir (Zovirax, GlaxoSmithKline)
- Valacyclovir (Valtrex, GlaxoSmithKline)
- Famciclovir (Famvir, Novartis)
- Penciclovir (Denavir, Novartis)
- Ganciclovir (Cytovene, Roche)
- Ribavirin (Virazole, ICN Pharmaceuticals)
- Foscarnet (Foscavir, AstraZeneca)
- Valganciclovir (Valcyte, Hoffman-LaRoche)
- Cidofovir (Vistide, Gilead Sciences)
- Research and Development
- Baraclude
- Truvada
- Telbivudine
- Viramidine
- Capravirine
- Elvucitabine
- Epzicom
- Etravirine (TMC125)
- GW5634
- MIV 150
- Pradefovir
- Reverset
- TMC278
- Valopicitabine
- Valtorcitabine
- BILR 355
- Calanolide A
- DPC 961 and DPC 963
- GW8248
- MCC-478
- MIV-310
- Market Size and Growth
- Competitive Analysis
Chapter Four: Protease Inhibitors
- Overview
- Description of Products
- Single Agents
- Saquinavir (Fortovase, Hoffman-LaRoche; Invirase, Hoffman-LaRoche)
- Nelfinavir (Viracept, Agouron Pharmaceuticals)
- Indinavir (Crixivan, Merck)
- Ritonavir (Norvir, Abbott Laboratories)
- Amprenavir (Agenerase, GlaxoSmithKline
- Fosamprenavir (Lexiva, Vertex and GlaxoSmithKline)
- Atazanavir (Reyataz, Bristol-Myers Squibb)
- Combination Protease Inhibitors
- Lopinavir and Ritonavir (Kaletra, Abbott Laboratories)
- Research and Development
- Tipranavir (PNU-140690)
- GW640385 (VX-385)
- TMC-114
- BMS232632
- RO033-4649
- VX-950
- Market Size and Growth
- Competitive Analysis
Chapter Five: Other Antivirals
- Overview
- Description of Products
- Aldara
- CytoGam
- Flumadine
- Fuzeon
- Infergen
- Pegasys
- Pegasys + Copegus
- Rebetol, Rebetron
- Relenza
- RespiGam
- Symmetrel
- Synagis
- Tamiflu
- Vistide
- Research and Development
- Attachment and Fusion Inhibitors
- Gene Therapies
- Integrase Inhibitors
- Maturation Inhibitors
- Zinc Finger Inhibitors
- Antisense Drugs
- Cytokines
- Other
- Market Size and Growth
- Competitive Analysis
Chapter Six: Issues and Trends
- Introduction
- Antiviral Drug Resistance
- HIV Drug Cost Controversy
- Antiretroviral Treatment Regimens
- HIV and Women
- Global Surveillance
- Biochemical Prevention and Treatment of Viral Infections
- New Treatment for Hepatitis C
- Costs and Funding of HIV Treatment
- Access to HIV/AIDS Treatment
Chapter Seven: Total Market Size and Forecast
- Overview
- Total Market Size and Forecast
chapter Eight: Corporate Profiles
- Introduction
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline
- MedImmune, Inc.
- Merck & Company, Inc.
- Novartis Pharmaceuticals Corporation
- Roche
- Schering-Plough Corporation
APPENDIX: Company Names and Addresses
List of Exhibits
Chapter One: Executive Summary
- Table 7-1: The World Market for Antiviral Drugs 2002-2009
- Figure 7-1: The World Market for Antiviral Drugs 2002-2009
Chapter Two: Introduction
- Table 2-1: Host Cell Receptors
- Table 2-1: Estimated World and U.S. Incidence of Viral Infections
- Figure 2-1: Estimated World and U.S. Incidence of Leading Viral Infections
- Table 2-2: World Population by Selected Geographical Region, 2004-2050
- Figure 2-2: World Population by Selected Geographical Region, 2003-2050
- Table 2-3: Estimated World Population by Age and Geographical Region, 2004
- Figure 2-3: Estimated World Population by Age and Geographical Region, 2004
Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors
- Table 3-1: Currently Available Nucleoside Reverse Transcriptase Inhibitors
- Table 3-2: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors
- Table 3-3: Currently Available DNA Polymerase Inhibitors
- Table 3-4: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors in Development (Product, Developer, Phase)
- Table 3-5: The Market for Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2002-2009
- Figure 3-1: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market 2002-2009
- Table 3-6: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Infection Type, 2004
- Figure 3-2: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Infection Type, 2004
- Table 3-7: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Geographic Region, 2004
- Figure 3-3: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Geographic Region, 2004
- Table 3-8: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 3-4: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share by Leading Suppliers 2004
- Table 3-9: Estimated Sales and Market Share of Top Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2004
- Figure 3-5: Estimated Market Share of Top Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor , 2004
Chapter Four: Protease Inhibitors
- Table 4-1: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
- Table 4-2: Protease Inhibitors in Development (Product, Developer, Phase, Earliest Approval Date)
- Table 4-3: The Market for Protease Inhibitors 2002-2009
- Figure 4-1: Protease Inhibitor Market 2002-2009
- Table 4-4: Protease Inhibitor Market Estimated Products Sales by Geographic Region, 2004
- Figure 4-2: Protease Inhibitor Market Market Share by Geographic Region, 2004
- Table 4-5: Protease Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 4-3: Protease Inhibitor Market Estimated Market Share by Leading Suppliers 2004
- Table 4-8: Protease Inhibitor Market Estimated Sales of Top Protease Inhibitors 2004
- Figure 4-4: Protease Inhibitor Market Estimated Market Share of Top Protease Inhibitors, 2004
Chapter Five: Other Antivirals
- Table 5-1: Currently Available Other Antivirals (Type, Brand, and Manufacturer)
- Table 5-2: Other Antivirals in Development (Product, Developer, Phase, Earliest Approval Date)
- Table 5-3: The Market for Other Antivirals 2002-2009
- Figure 5-1: The Market for Other Antivirals 2002-2009
- Table 5-4: The Market for Other Antivirals Estimated Products Sales by Infection Type, 2004
- Figure 5-2: The Market for Other Antivirals Market Share by Infection Type, 2004
- Table 5-5: The Market for Other Antivirals Estimated Products Sales by Geographic Region, 2004
- Figure 5-3: The Market for Other Antivirals Market Share by Geographic Region, 2004
- Table 5-6: The Market for Other Antivirals Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 5-4: Other Antiviral Market Estimated Market Share by Leading Suppliers 2004
- Table 5-7: Other Antiviral Market Estimated Sales of Other Antiviral Products 2004
- Figure 5-5: Other Antiviral Market Estimated Market Share of Top Other Antiviral Products, 2004
Chapter Six: Issues and Trends
- Table 6-1: Women (15 to 49) Living with HIV/AIDS by Region 2004
- Table 6-2: Funding for HIV/AIDS
- Table 6-3: Access Needs of Adults and Children with HIV by Region 2004
- Table 6-4: Antiretroviral Access for HIV Infected Individuals by Region in the Developing World
Chapter Seven: Total Market Size and Forecast
- Table 7-1: The World Market for Antiviral Drugs 2002-2009
- Figure 7-1: The World Market for Antiviral Drugs 2002-2009
- Table 7-2: World Market for Antiviral Drugs by Type 2002-2009
- Figure 7-2: The World Market for Antiviral Drugs Revenues by Type 2002-2009
In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.
We were unable to search inside this report.
No results matched your search criteria.
Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).
Please note that your term must be at least three characters long and numbers will be blocked by the # sign.
Most Popular Research
- Retail Clinics Trends Overview
- Walk-in Store Clinics (Retail Clinics) Bring Healthcare to Consumers, While Other Venues Wait for Patients
- China's 3.2 Billion-Dollar In Vitro Diagnostics Market: Opportunity for Surplus Growth
- The Global Market for Medical Devices, 8th Edition (40+ Specific Device Markets and 23 Country Markets Forecasted to 2022)
- The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 11th Edition
- No Easy Road for POC Molecular Diagnostics in Developing World: White Paper